BS01 in Patients With Retinitis Pigmentosa
ConditionRetinitis Pigmentosa
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBionic Sight LLC
About this trial
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Eligibility criteria
Qualifiers
Confirmed diagnosis of retinitis pigmentosa
At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.
Disqualifiers
Prior receipt of any AAV gene therapy product
Large amplitude nystagmus
Trial design
Treatments tested in this trial
- BS01
Treatment groups
20 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov